John Libbey Eurotext

Hématologie

Ne pas interrompre ou réduire la dose d’ibrutinib améliore le pronostic dans le traitement de la leucémie lymphoïde chronique Volume 23, numéro 4, Juillet-Août 2017

  • [1] Byrd J.C., Brown J.R., O’Brien S. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.
  • [2] Advani R.H., Buggy J.J., Sharman J.P. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88-94.
  • [3] European Medicines Agency. IMBRUVICA (ibrutinib) summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003791/WC500177775.pdf. Accessed 22 March 2017.
  • [4] Barr P.M., Brown J.R., Hillmen P. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood. 2017;129:2612-2615.